Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Melanoma 1Medulloblastoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Advanced Fallopian Tube Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 19Temozolomide 16Radiotherapy 10Specimen Handling 7Blood Specimen Collection 7Radiation 6Bevacizumab 5Nivolumab 4Cyclophosphamide 4Biopsy 4vorasidenib 3trametinib 3pembrolizumab 3olaparib 3fludarabine 3dabrafenib 3Watchful Waiting 3Surgical Procedures, Operative 3Magnetic Resonance Imaging 3Drug Therapy 3olutasidenib 2lutetium Lu 177 dotatate 2fluorodopa F 18 2fluciclovine F-18 2entrectinib 2contrast agent BR1 2Restraint, Physical 2Radiosurgery 2Microdialysis 2Flucytosine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Glioma × Diphtheria-Tetanus Vaccine × Clear all
NCT05096481 2026-05-11

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡